NEUP (Neuphoria Therapeutics) Beginning Cash Position: $22.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEUP Neuphoria Therapeutics Inc NEUP
23 GF Score
Price $3.43
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Beginning Cash Position?

Neuphoria Therapeutics NEUP -3.26% 23 Beginning Cash Position is $22.25 Mil as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Neuphoria Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $22.25 Mil.

Neuphoria Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($14.29 Mil) to Dec. 2025 ($13.73 Mil) but then increased from Dec. 2025 ($13.73 Mil) to Mar. 2026 ($22.25 Mil).

Neuphoria Therapeutics's annual Beginning Cash Position declined from Jun. 2023 ($22.89 Mil) to Jun. 2024 ($12.18 Mil) but then increased from Jun. 2024 ($12.18 Mil) to Jun. 2025 ($12.69 Mil).

Neuphoria Therapeutics Beginning Cash Position Related Terms

Neuphoria Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Beginning Cash Position Chart

Neuphoria Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 19.61 22.89 12.18 12.69

Neuphoria Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.42 17.12 14.29 13.73 22.25
NEUP
23GF Score
Neuphoria Therapeutics Inc NEUP
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $22.25 Mil mean?
Neuphoria Therapeutics (NEUP) has a Beginning Cash Position of $22.25 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Beginning Cash Position too high?
Neuphoria Therapeutics' current Beginning Cash Position is $22.25 Mil. Overall, Neuphoria Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Beginning Cash Position compare to PLRZ and SKYE?
Neuphoria Therapeutics' Beginning Cash Position of $22.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Beginning Cash Position is $22.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Beginning Cash Position of $22.25 Mil. The current Beginning Cash Position is $22.25 Mil. Neuphoria Therapeutics' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Beginning Cash Position is $22.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
23GF Score

Get the complete analysis for NEUP

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.43
Price